Valtis, Y., Sandhu, K., Faramand, R., Zhang, A., Miller, K., Hill, L., Muhsen, I., Othman, T., Luskin, M., Chen, E., Oliai, C., Lill, G., Cassaday, R., Kopmar, N., Logan, A., Connor, M., Hilal, T., Park, J., Solh, M., Guzowski, C., Leonard, J., Tan, V., Jeyakumar, N., Srinagesh, H., Kumaran, M., Hoeg, R., Koura, D., Dykes, K., Stock, W., Gatell, V. I., Jackson, C., Oluwole, O., Dholaria, B., O'Dwyer, K., Moore, J., Ulrickson, M., Al-Darobi, A., Byrd, K., Tsai, S., O'Connor, T., Wang, E., McCauley, R., Jamy, O., Mohty, R., Roloff, G., Sutherland, K., Aldoss, I., Shah, B., Muffly, L., Frey, N. (2025). Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis. Blood. https://doi.org/10.1182/blood-2025-2715